MedTrace Logo

Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

NCT03043287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 420

Last updated 2020-02-05

No results posted yet for this study

Summary

This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

Conditions

  • Urinary Bladder, Overactive

Interventions

BIOLOGICAL

onabotulinumtoxinA

onabotulinumtoxinA (BOTOX®)100 to 200 U

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Dana Fetterolf · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-12
Primary Completion
2019-09-09
Completion
2019-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03043287 on ClinicalTrials.gov